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RESEARCH ARTICLE
Generic medicines and generic 
substitution: contrasting perspectives 
of stakeholders in Ireland
A. O’Leary1,2, C. Usher1*, M. Lynch2, M. Hall3, L. Hemeryk3, S. Spillane1, P. Gallagher2 and M. Barry1,3
Abstract 
Background: The Health (Pricing and Supply of Medical Goods) Act 2013 passed into law in July 2013 and legislated 
for generic substitution in Ireland. The aim of the study was to ascertain the knowledge and perceptions of stakehold-
ers i.e. patients, pharmacists and prescribers, of generic medicines and to generic substitution with the passing of 
legislation.
Methods: Three stakeholder specific questionnaires were developed to assess knowledge of and perceptions to 
generic medicines and generic substitution. Purposive samples of patients, prescribers and pharmacists were ana-
lysed. Descriptive quantitative and qualitative analyses were undertaken.
Results and discussion: A total of 762 healthcare professionals and 353 patients were recruited. The study high-
lighted that over 84 % of patients were familiar with generic medicines and are supportive of the concept of generic 
substitution. Approximately 74 % of prescribers and 84 % of pharmacists were supportive of generic substitution in 
most cases. The main areas of concern highlighted by the healthcare professionals that might impact on the success-
ful implementation of the policy, were the issue of bioequivalence with generic medicines, the computer software 
systems used at present in general practitioner (GP) surgeries and the availability of branded generics. The findings 
from this study identify a high baseline rate of acceptance to generic medicines and generic substitution among 
patients, prescribers and pharmacists in the Irish setting. The concerns of the main stakeholders provide a valuable 
insight into the potential difficulties that may arise in its implementation, and the need for on-going reassurance and 
proactive dissemination of the impact of the generic substitution policy.
Conclusion: The existing positive attitude to generic medicines and generic substitution among key stakeholders 
in Ireland to generic substitution, combined with appropriate support and collaboration should result in the desired 
increase in rates of prescribing, dispensing and use of generic medicines.
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Background
The escalating cost of public provision of prescrip-
tion medicines has become a global challenge [1, 2]. In 
Ireland, prescription medicines are provided to citi-
zens free of charge or on a subsidised basis through the 
taxation-based public health service. State expenditure 
on prescribed medicines has grown steadily since the 
introduction of the Health Act, 1970, which provided for 
the provision of prescribed medicines free of charge to 
eligible persons. This act resulted in the establishment of 
the General Medical Services (GMS) scheme, which cov-
ers approximately 40 % of the Irish population as deemed 
eligible by means testing [3]. For persons not covered 
under the GMS scheme, State subsidisation of medicine 
costs occurs through the ‘community drug schemes’, 
which include the Drugs Payment (DP) scheme, Long 
Term Illness (LTI) scheme and High Tech Drug (HTD) 
scheme. The State pays the cost of regular medicines 
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above and beyond a threshold per family which stands 
at €144 per month as of 2015 (DP scheme). The State 
also bears the cost of complex expensive drugs such as 
oncology medicines dispensed in the community (HTD). 
Additionally, the State pays the cost of drugs prescribed 
for specified medical conditions which are included 
within the LTI scheme, for example, diabetes mellitus or 
epilepsy. Medicines are provided to patients through the 
above schemes by community pharmacies which enter 
into contractual arrangements with the Irish health ser-
vice. Drug costs borne by the pharmacies are recouped 
from the health service following submission of dispens-
ing records and a dispensing fee per item is also paid to 
pharmacists [3].
Expenditure on medicines under the GMS and com-
munity drug schemes increased greater than five-fold 
over the decade 1997 to 2007 [4], and in 2010 Ireland 
spent more on pharmaceuticals than any other European 
country on a per capita basis [5] with public expendi-
ture amounting to €1.9 billion [6]. In the years 2011–
2013, costs have remained at this level. Following this, 
the 2011–2016 Programme for Government in Ireland 
made commitments to reduce the State’s pharmaceutical 
bill and reduce costs for consumers, including through 
greater generic medicine usage [7]. Generic medicines 
provide an opportunity for savings on expenditure on 
medicines due to their typically lower price, and generic 
substitution policies aimed at promoting the utilisation 
of generic medicines have been introduced in several 
countries with considerable success [3–8]. In Europe, the 
rate of generic medicines use exceeds 50 % in some coun-
tries, and is rising slowly in other countries in tandem 
with a concerted cost containment policy for healthcare 
in the EU [9]. Underuse of generic medicines, meanwhile, 
is considered to be one of the leading causes of economic 
inefficiency in healthcare [2].
Ireland has traditionally had a low rate of generic medi-
cines use with rates of approximately 18 % in the 1990s 
and minimal increases in the early part of the 21st cen-
tury [10–12]. Postulated contributory factors for this low 
uptake include negative perceptions of generic medicines 
by prescribers and patients; relatively small price differ-
ential between proprietary medicines and their generic 
versions; the absence of any legal provision which either 
permitted or required pharmacists to undertake generic 
substitution; and the limited extent of prescribing using 
the drug’s international non-proprietary name (INN) 
[8]. More recently, generic uptake in Ireland was found 
to undergo a considerable increase during the period 
2010–2012. In an analysis examining ten leading multi-
ple-source off-patent pharmaceuticals, the market share 
of generic manufacturers for these products was found to 
increase from 24 to 50  % within the GMS scheme, and 
from 14 to 36 % within the DP scheme during these years 
[8].
Increases in generic medicine uptake are facilitated 
where reimbursement policies or financial incentives are 
firmly in place to promote the prescribing and dispens-
ing of generic medicines [9]. The passing of legislation in 
Ireland, in the form of the Health (Pricing and Supply of 
Medical Goods) Act, 2013, has provided a mechanism 
for the introduction of generic substitution of medici-
nal products based on interchangeability at active sub-
stance level, and for a system of internal reference pricing 
[13]. Future enabling policy measures may include the 
introduction of compulsory INN prescribing, as recom-
mended by the International Monetary Fund under the 
economic adjustment programme for Ireland [8]. The 
success of any measure to promote generic substitution 
depends, however, on the support of the key stakehold-
ers, the barriers to substitution in terms of existing per-
ceptions, and the supports in place to facilitate a smooth 
transition to generic substitution by pharmacists [9]. The 
aim of this study was to assess the knowledge and per-
ceptions of patients, pharmacists and prescribers (spe-
cifically medical doctors) in early 2013 towards generic 
medicines and substitution, prior to the introduction 
and implementation of the Health (Pricing and Supply of 
Medical Goods) Act 2013 (July 2013).
Methods
Quantitative survey methodology was used to achieve the 
study end-points. Surveys were developed for patients, 
prescribers and pharmacists following a literature review 
of published studies [14–19], and included both struc-
tured and unstructured questions. Surveys were piloted 
on a sample of all stakeholders prior to wider dissemina-
tion. Surveys contained 16 (prescriber survey), 20 (phar-
macist survey) and 23 (patient survey) items in total. 
Patient surveys consisted of three sections: (1) character-
istics of patient (age, gender, number of chronic diseases 
and number of prescribed medicines) (2) knowledge 
of a generic medicine, and (3) perspectives on previous 
generic substitution and willingness to accept substitu-
tion. The survey for prescribers and pharmacists con-
sisted of two parts: (1) demographics of respondents 
(professional status, number of years in practice) and (2) 
assessment of their perceptions on generic substitution, 
acceptance level and perceived barriers. Ethical approval 
for the study was obtained through the St. James’s Hos-
pital/Tallaght Hospital Research Ethics Committee (No. 
2012/12/29).
Purposive sampling methods were used to identify 
respondents to facilitate data collection in the short dura-
tion of time available. Survey administration methods 
were stakeholder specific. One-to-one interviews were 
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conducted with patients, all pharmacists completed an 
on-line version of the survey administered using Survey 
Monkey™, while prescribers either completed an on-line 
version or self-completed a paper version.
Stakeholder recruitment
Patients
Patients were recruited in both the primary and second-
ary care settings. Patients attending community phar-
macies where pharmacy students were training under 
the National Pharmacy Internship Programme were 
recruited over a 6 week period (June–July 2013). Patients 
attending an outpatient (OP) clinic in a University Teach-
ing Hospital were recruited between April and May 2013.
All patients gave written consent prior to participa-
tion. Patients were interviewed face-to-face by pharmacy 
interns in community pharmacies and research nurses in 
the OP setting. Patients were aged 18 years or over. Chil-
dren were excluded from the study, as were patients with 
known cognitive impairment.
Pharmacist and prescriber recruitment
Pharmacists registered with the Pharmaceutical Society 
of Ireland (PSI; the regulatory authority for pharmacists 
in Ireland) received an invitation to participate in the 
survey through the monthly electronic newsletter from 
the PSI with a link to the on-line survey URL. Surveys 
were completed between March 18th and April 1st 2013. 
Prescribers were invited to participate, either through a 
personal email from the study authors with a link to the 
on-line web URL, or by completion of a hand written sur-
vey distributed at educational fora for general practition-
ers in the University Teaching Hospital, between January 
and July 2013.
Data collection and analysis
Patient and prescriber hand-completed surveys were 
entered into a coded database by one study investiga-
tor, while pharmacist survey data was downloaded 
from the on-line website (Survey Monkey™). Pooled 
datasets underwent a systematic quality control proce-
dure to identify data anomalies. The patient dataset was 
screened for date of birth data anomalies, and implau-
sible data entry errors. Anomalous data were checked 
with raw questionnaire forms and subsequently cor-
rected. To validate the categorical variable data, a ran-
dom sample of the patient questionnaires (10  %) were 
selected, and a second study investigator undertook a 
double data entry exercise. The datasets were matched 
and an error difference of <1  % was determined cor-
relating with an acceptable difference. All prescriber 
questionnaires available for data entry underwent a 
double data entry process which again achieved a <1 % 
difference in rate of error. Narrative data received in 
response to open-ended questions in the three surveys 
underwent a process of enrichment where applica-
ble, and answers were categorised based on identified 
themes. This was conducted by the first author who 
read and re-read the narratives to capture an overall 
sense. Themes and sub-themes were then established 
and checked by the second and third authors until con-
sensus was reached.
Final datasets were imported into SAS (Version 9.1®) 
for descriptive and statistical analysis. Logistic regres-
sion was used to determine factors that predict a patient’s 
knowledge of generic medicine. Independent variables 
considered were age, gender and knowledge of generic 
medicines.
Results
Quantitative analysis
A total of 353 patients, 100 prescribers and 662 phar-
macists (response rate 17  %) were included in the anal-
yses. The rate of non-participation was not recorded 
for the patient or prescriber cohort due to the nature of 
sampling.
Patient cohort
In the patient cohort, 133 were recruited from a hospi-
tal-based out-patient department and 220 patients from 
primary care. There was a higher prevalence of female 
respondents over male (55  %), and 43  % of the total 
cohort were over 60  years of age. The mean number of 
chronic diseases per patient was 1.4 (range 0–7). Forty-
two percent of patients qualified for free medicines under 
the GMS scheme, while 27  % paid for their medicines 
privately. Cardiovascular disease accounted for the co-
morbid profile of 62 % of patients, while 37 % were pre-
scribed more than 5 medicines.
Prescriber and pharmacist cohorts
Minimal demographic details were obtained for the 
healthcare provider cohort.
The time in practice profile of respondents among pre-
scribers was generally longer than that of the pharmacist 
cohort with 33  % practising for more than 30  years, as 
compared with the pharmacist cohort, where 40 % were 
in practice for less than 10 years (Table 1). Both cohorts 
were delivering healthcare almost exclusively in the pri-
mary care setting: 97 % for prescribers and 93 % for phar-
macists (Fig. 1a, b). 
Patients’ knowledge of the term ‘generic medicine’
The majority of patients were familiar with the term 
‘generic medicine’ (84 %) based on the accepted definition 
of the term. Familiarity with the term decreased in older 
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patients with 64 % aware of the term in the >80 years age 
group. While the community-based patients were less 
likely to be receiving medication for cardiovascular dis-
ease [Odds Ratio (OR) 0.06, 95 % CI 0.03, 0.14], there was 
no difference between the groups with respect to their 
familiarity with/knowledge of the term “generic medi-
cine” (OR 1.64, 95 % CI 0.88, 3.04).
Patients were asked a series of questions specifically 
examining their knowledge of the term ‘generic medi-
cine’ (Table  2). Patients agreed that generic medicines 
were the same and cheaper than branded medicines (81 
and 82 % respectively), while they were unsure whether 
generic versions were available for all medicines.
Patients’ acceptance of generic substitution by healthcare 
providers
When asked how willing they would be to accept a 
generic medicine for a branded product, 76 % of patients 
said they would be willing to do so if prescribed by their 
GP. This compares with 58  %, who would be willing to 
accept a generic substitute by the pharmacist.
Patients’ experience with generic medicines
Some 42  % of the cohort had a previous experience of 
switching from a branded to a generic medicine, with the 
majority of these initiated by the GP (73 %), although a 
smaller proportion reported switches initiated by the 
pharmacist (27 %). Of the 42 % of patients currently tak-
ing a generic medicine, a significant number reported a 
change in packaging (90 %) and a change in appearance 
or shape (67 %). However, despite these changes, it had 
little or no impact on self-reported compliance (Table 3).
Prescribers and pharmacists support for generic medicines 
and generic substitution
Prescribers supported generic substitution for original 
branded drugs in most cases (74  %), and agreed there 
were some situations where it was not appropriate. This 
compares to 84 % of pharmacists who supported generic 
substitution in most cases. Of the prescribers surveyed, 
20 % supported generic substitution for original branded 
drugs in all cases where a generic was available, compared 
to 16 % of pharmacists. Overall, support for generic sub-
stitution was evident in the responses provided.
Both prescribers and pharmacists were broadly in 
agreement with the types of information they consid-
ered important to impart to patients with therapeutic 
Table 1 Area of  practice for  healthcare professional 
respondents
Area of practice— 
prescribers
Area of practice— 
pharmacists
General practitioner 97 % Community pharmacist 75 %
Hospital-based consultant 2 % Hospital-based pharmacist 16 %
Non-clinical role 1 % Non-clinical role 9 %
40%
35%
17%
4% 3%
60%
9%
2%
7%
3%
0%
10%
20%
30%
40%
50%
60%
70%
a
b
Reassurance 
regarding 
therapeuc 
equivalence
Reassurance 
regarding 
quality
Reassurance 
regarding 
saey
Cost savings Availability
Prescribers
Pharmacists
44.30%
11.30%
44.30%
52.10%
5.60%
42.30%
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
Yes No Maybe
Prescribers
Pharmacists
Fig. 1 a Number of years in practice—prescribers. b Number of 
years in practice—pharmacists
Table 2 Patients’ knowledge of generic medicines
Yes (%) No (%) Do not know (%)
Generic medicines are the same as branded medicines 81 7 12
Generic medicines are as effective as branded medicines 76 11 13
Generic medicines are as safe as branded medicines 75 5 20
Generic medicines are available for all branded medicines 16 38 46
Generic medicines are cheaper than branded medicines 82 4 8
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equivalence and quality of generic medicines considered 
of greatest importance by both healthcare professionals 
(Table  4). Both stakeholder groups agreed that patients 
were accepting of the concept of generic substitution, 
with 44 % of prescribers responding in favour, compared 
to 52  % among pharmacists. Both groups considered 
it likely that a further 40  % or more of patients could 
be willing to accept generic substitution. A compari-
son of other perspectives of healthcare professionals on 
generic substitution is shown in Table 5. The influence of 
hospital-initiated prescribing is indicated by the propor-
tion of healthcare professionals who would be less likely 
to undertake substitution if a branded product was pre-
scribed in the hospital setting (13–16 %). 
Thematic analysis of narrative comments
Patients’ views on generic medicines
Narrative comments which were suggestive of potential 
patient barriers to generic substitution included refer-
ences to lack of comparable effectiveness to branded 
medicines (often grounded in experience), absence 
of confidence in generic medicines and experience of 
adverse effects.
“….not as good as….don’t work as well…”
Patients described the potential for confusion and anxi-
ety with changes in packaging and appearance.
“…..Confusing as different names on boxes… stickers 
cover the information…”.
A number of patients felt that there was a need for 
more research into the effectiveness of generic medicines.
“…..Felt better on branded medicine, felt it worked 
better…”
A number of patients stated a preference to stay on 
branded medicines rather than having to accept a generic 
medicine. The need for patients to be given additional 
information and time to consider generic substitution 
was fed back in open ended comments.
Several patients provided positive comments on 
generic medicines, and stated they were happy on 
generic medicines, and had no problems with them or 
experienced no adverse sequelae. Some went further to 
state that it made them more alert when switched.
“….It made me more alert and improved my compli-
ance…..”
Prescribers and pharmacists views on generic medicines 
and substitution
Prescribers were particularly concerned about the effect 
of generic substitution in vulnerable patient groups 
including the frail, the elderly, those on multiple medi-
cines, those with cognitive impairment and patients suf-
fering from anxiety. This was similarly represented in 
pharmacist feedback. A significant number of healthcare 
professional respondents commented on the potential for 
generic medicines to cause adverse effects, and for a con-
sequent adverse impact on patient compliance, ultimately 
leading to therapy failure. The potential effect of such 
drug-related problems on patient welfare was thought 
to be particularly worrying for patients with long-term 
chronic conditions including epilepsy and mental health 
problems. A contributory factor suggested by prescrib-
ers was possible confusion arising from repeated changes 
in packaging should different generic medicines be dis-
pensed to patients each month depending on cost.
“….There must be provisions made that prevent the 
changing of a patient’s generic medication every 
other month i.e. just because A is 1 cent cheaper 
than B another substitution should not be made. 
This would be extremely confusing for patients and 
health care……”
The availability of ‘branded generics’ in Ireland was also 
postulated to contribute to potential confusion among 
patients.
…..It would be better if generic products didn’t have 
their own brand names….
For both pharmacists and prescribers, there was con-
sensus on the need for specific drugs to be exempt from 
substitution for clinical and safety reasons. This was 
Table 3 Patients’ experience with  switching to  a generic 
medicine
Yes (%) No (%)
Change in packaging 90 10
Change in shape or appearance 67 33
Effect on compliance 14 86
Table 4 Perceptions of healthcare providers around impor-
tance of information to be provided to patients
Prescribers (%) Pharmacists (%)
Therapeutic equivalence 40 60
Quality 35 19
Safety 17 12
Cost savings 4 7
Availability 3 3
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especially true for drugs with narrow therapeutic indices 
such as antiepileptic drugs, modified release formula-
tions, multiple ingredient products and the unusual situ-
ation when different brands were licensed for different 
indications. Both cohorts were consistent in the explicit 
and comprehensive examples of medicines considered 
appropriate to exempt.
There were additional, specific concerns highlighted 
in relation to the absence of firm evidence regarding 
the therapeutic equivalence and the quality of generic 
medicines.
…….‘Not convinced of equal efficacy of generics- 
more evidence needed’….
The potential for altered formulations and additional 
excipients to cause adverse effects was raised.
Both stakeholders alluded to the limited potential for 
actual cost savings to be made from generic substitu-
tion in Ireland given the small price differential between 
generics and branded medicines in place in Ireland in the 
past.
….‘Biggest problem is the high cost of generics, with 
little or often no savings available’……
A practical barrier to effective implementation of 
generic substitution identified in the responses was com-
puter software systems in GP practices, which do not 
facilitate a ‘user friendly system to allow generic prescrib-
ing/substitution by GP computer system’.
In general however there was a positive attitude 
towards generic medicines and generic substitution.
….‘Generic prescribing is long overdue, I have pre-
scribed generically for years. My patients gained sig-
nificantly with no loss of effectiveness’…..
Discussion
The aim of this study was to assess the knowledge and 
perceptions of Irish patients and Irish healthcare pro-
viders to generic medicines and generic substitution 
prior to the implementation of the Irish nationwide 
generic substitution policy. Our findings suggest that the 
majority of patients demonstrated a good understand-
ing of generic medicines (84  %). Another recent study 
of patient perceptions of generic medicines in the Irish 
setting, reported that 31 % of patients had no knowledge 
of generic medicines, compared to the lower rate of 16 % 
in our study [20]. This may be explained by the different 
method of surveying patients, i.e. in-depth qualitative 
interview technique as compared with survey method-
ology. The potential for acquiescence bias may be higher 
with survey methodology than face-to-face interviewing. 
Over 80 % of our patient cohort was aware that generic 
medicines are the same as branded medicines and less 
expensive, while 75  % perceive them to be as effective 
and as safe as their branded counterparts. Although 
previous studies have reported that patients perceived 
generic medicines to be inferior or not as effective as 
branded products (mainly due to the price differential 
between the two implying generics were of lower qual-
ity) [14, 18, 21–23], this perception did not dominate 
the feedback in our patient cohort. Patients were, how-
ever, less sure of the availability of generic medicines 
for all branded products, perhaps not a surprising find-
ing. This overall enhanced knowledge among patients 
of generic medicines may in part be due to widespread 
publicity across the media in the lead up to the passing 
of the Health (Pricing and Supply of Medical Goods) Act 
in July 2013 which introduced generic substitution. This 
would appear to support the benefits of providing edu-
cation and information campaigns to inform the public. 
Table 5 Comparative views of healthcare providers (prescribers and pharmacists) on generic substitution
Yes (%) No (%) Maybe (%)
Do you think patient care may be affected in any way by generic substitution?
 Prescriber 24 51 25
 Pharmacist 14 48 38
Would you be more likely to opt out of prescribing/dispensing a generic medicine is a hospital prescriber had prescribed a branded product?
 Prescriber 16 62 21
 Pharmacist 13 68 20
Are you comfortable with the concept of generic substitution of a branded medicine?
 Prescriber
  If undertaken by a pharmacist, of a branded product prescribed by you 58 18 23
 Pharmacist
  With undertaking generic substitution of a branded product prescribed by a prescriber 86 3 12
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This is underpinned by the recent review by Hasali et al. 
who reported an upward trend in patient knowledge and 
confidence towards the use of generic medicines follow-
ing introduction of generic substitution policies, and a 
similar trend may become apparent here [24].
Patients also reported a high rate of willingness to 
accept substitution from either prescribers or pharma-
cists, although there was an indication that GP-initiated 
substitution was favoured over pharmacist-initiated sub-
stitution. Further education initiatives would be useful 
in providing further reassurance to patients who have 
remaining doubts about the effectiveness of generic 
medicines, or may be resistant to change, as has been 
reported previously [14, 18, 21, 22, 25]. Appropriate and 
adequate patient education for patients prior to switching 
is necessary, and there is robust evidence that an inter-
disciplinary approach can optimise patient acceptance to 
generic medicines and substitution. Healthcare profes-
sionals play a significant role in educating patients about 
generic medicines, and several studies have highlighted 
positive endorsement from prescribers and pharmacists 
as important drivers for patients accepting a generic sub-
stitute [14, 26–29]. The input of both prescribers and 
pharmacists is therefore required to improve confidence 
of patients in generic medicines, and to accept generic 
substitutes for branded medicines. This may incur addi-
tional time explaining the concepts and rationale for 
generic substitution to their patients, which in the time 
constrained primary care setting may prove difficult.
Almost half of those patients surveyed had experi-
enced a switch to a generic medicine in the past. This 
was associated with significant changes in packaging, 
shape and appearance compared to their existing medi-
cines, and this could occur repeatedly on subsequent 
occasions when the medicine was dispensed. Previous 
studies have reported on the potential for generic substi-
tution to result in significant patient confusion, and anxi-
ety [17, 22, 30]. While confusion was reported among 
some patients who were switched in this study, it was not 
reported to impact on compliance. It is acknowledged 
however, that the reliability of self-reported compliance 
as captured in this survey method may be associated 
with considerable uncertainty [31]. A recent US study has 
reported increased odds of non-persistence associated 
with changes in pill colour among patients with epilepsy 
[32]. While persistence is a surrogate marker of compli-
ance, the need to minimise frequent changes in pack-
aging should be addressed through consultation with 
pharmacists, who have a professional responsibility to 
ensure that changes do not impact negatively on patients 
through appropriate patient counselling, focussed stock 
management and improved terms from suppliers of 
generic medicines. Restriction on the availability of 
branded generics may also be merited to avoid confusion.
The majority of healthcare professionals supported 
generic substitution in ‘most cases’, with a larger pro-
portion of pharmacists supportive (84  %) compared 
with prescribers (74  %). The new Act implemented in 
2013 provides that all pharmacists in Ireland will now 
be required to offer patients the opportunity to substi-
tute a prescribed non-generic, interchangeable medicinal 
product with a less expensive generic alternative. Previ-
ous to the Act, pharmacists were required to dispense 
the medicinal product as prescribed by the healthcare 
provider. Where the patient declines the substitution of 
a medicinal product, the price of which is at or below 
the reference price set for that product, the patient will 
be responsible for paying the pharmacist the difference 
between the reference price and the price of the branded 
product dispensed. There is provision in the Act whereby 
a prescriber of a non-generic medicine may specify on 
the prescription “do not substitute” beside the name of 
the medicinal product concerned. The apparent ration-
ale for this provision is to acknowledge a prescriber’s 
professional discretion in this regard which they would 
normally exercise to protect patients with specific clini-
cal needs from being adversely impacted by substitution. 
Similarly, there is a provision for patients to opt out of 
accepting generic medicines, but will be obliged to incur 
the additional cost of the difference in price between the 
generic medicine and the branded medicine. There are 
no financial incentives associated with implementation of 
the Act.
There was a correspondingly high level of ‘comfort’ 
with the concept of a national generic substitution policy, 
which is encouraging. Both prescribers and pharmacists 
perceived that patients would be willing to accept generic 
medicines, which was supported by patients’ perceptions 
as reported in this study. This may have stemmed from 
previous experiences of healthcare professionals with 
switching patients, and provides evidence of a baseline 
positive attitude to the pending national policy, which 
should impact in a constructive way on rates of uptake 
for generic substitution.
Misconceptions among healthcare professionals about 
generic medicines and generic substitution have previ-
ously been reported in the literature as barriers to effec-
tive implementation of generic substitution policies [14, 
15, 33]. While most healthcare professionals captured in 
this study did not perceive that substitution of branded 
medicines with generic versions would impact nega-
tively on the overall clinical care or therapeutic control 
of patients, concerns were raised in relation to specific 
patients particularly in frail, elderly, cognitively impaired 
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patients and those on multiple medicines. This is similar 
to previously published reports of attitudes of prescrib-
ers and pharmacists to generic medicines [17, 21, 30, 33, 
34]. The potential for negative consequences on compli-
ance if several medicines were switched simultaneously, 
sequentially or repeatedly was reported in this study. A 
small number of studies have reported decreased adher-
ence associated with generic substitution [33, 35, 36], 
although whether there may be an effect on patient com-
pliance in the Irish setting is unknown as yet, and may 
prompt the need for prospective persistence studies to 
assess the impact, if any. From a patient perspective, as 
self-reported by patients surveyed, compliance was unaf-
fected despite experiencing changes in packaging. This 
confirms the absence of an effect on compliance as pre-
viously reported by Van Wijk and Oleson [37, 38]. How-
ever, the degree to which social desirability may have 
confounded responses among patients in this study is 
unknown, but is recognised in the literature [31, 39].
Low perceived efficacy and safety is reported by the 
WHO, as a common reason for generic medicines’ 
underuse, in addition to prescribers’ concerns in relation 
to efficacy and therapeutic equivalence [40–42]. Con-
cerns have also arisen where small differences in bioavail-
ability have led to questions regarding true bioavailability, 
particularly in relation to drugs with narrow therapeutic 
indices [43]. Prescribers in particular, in our study, had 
reservations around the bioequivalence of generic medi-
cines. This perception was previously reported among 
Irish prescribers in the 1990s and also recently, so there 
appears to be a sustained uncertainty around generic 
medicines [10, 19]. Despite comments to the potentially 
inferior quality of generic medicines as compared with 
branded products, there is little in the literature to sub-
stantiate these claims.
Both prescribers and pharmacists provided several 
examples of specific medicines that they considered inap-
propriate for substitution, similar to those reported in the 
published literature [19, 44, 45]. These primarily focused 
on drugs with narrow therapeutic indices i.e. antiepi-
leptic drugs, digoxin, thyroxine, warfarin, in addition to 
multi-constituent and sustained-released formulations. 
There is no provision in the legislation for particular 
exempted medicines, but there is provision for prescrib-
ers to specifically state on prescriptions that the medi-
cation is not to be generically substituted. As provided 
for in the Act, however, one of the factors which render 
a product unsuitable to be added to the interchangeable 
list is if it has a narrow therapeutic index, which would 
mean it could not be safely substituted.
The supply and pricing arrangements for generic prod-
ucts have also been reported as possible deterrents to 
effective generic substitution implementation. While cost 
savings have been reported in other jurisdictions [21, 46], 
it has been reported that such policies may increase costs 
due to the impact on patient compliance and adverse 
clinical effects [47] and therefore erode any potential cost 
savings in the long term [45]. Doubts were raised in this 
study by healthcare professionals as to the actual cost sav-
ings that could be achieved following the introduction of 
the generic substitution policy. This was attributed to the 
relatively minor price differential that existed between 
branded medicines and their generic equivalents in the 
past, together with the availability of so-called “branded 
generics”. It will be important to monitor generic medicine 
use following the introduction of the new generics policy 
and to analyse and publicise actual cost savings achieved 
obtained from its implementation to all key stakeholders 
on an on-going basis, to demonstrate its benefits.
Patients, prescribers and pharmacists alluded to the 
potential increased risk of actual adverse effects asso-
ciated with generic medicines over branded products. 
Some of this was postulated in feedback to relate to 
altered excipients and manufacturing ingredients. Excipi-
ents or inactive ingredients in generic medicines may 
differ from originator medicines [48]. Adverse events or 
allergies to such ingredients have been reported in the 
literature, but the extent of the problem is low [48]. How-
ever, vigilance regarding the potential for harm is rec-
ommended among healthcare professionals, with some 
jurisdictions going so far as to advocate increased sur-
veillance and reporting systems focused on adverse event 
reporting for generic medicines [49, 50].
Both GPs and pharmacists referred to the need for 
improvements to GP computer software systems to facili-
tate easier selection when issuing prescriptions of generic 
medicines from the ‘picking list’, or the most cost effective 
generic medicine. This might support the introduction of 
a more user friendly information technology system that 
facilitates selection of generic medicines for prescribers, 
within the confines of a limited fixed time consultation, 
or the availability of a national formulary medicines’ list.
Strengths and limitations of the study
While this study investigated simultaneously the percep-
tions of the key stakeholders in Ireland to generic medi-
cines, it has some limitations. The purposive sampling 
method used for recruitment may not reflect the broader 
views of these stakeholders, and therefore generalisability 
to the entire population of stakeholders may be limited. 
In particular, the views of prescribers may be underrep-
resented in this study due to the small sample size. In 
addition, the prescriber cohort was overrepresented by 
physicians with many years in practice whose responses 
may be subject to bias. The large sample size obtained 
for the pharmacist survey is less open to external validity 
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bias. The patient cohort may also be less open to selec-
tion bias as the sample was drawn from a broad spectrum 
of patients who obtain their medicines through a variety 
of subsidised schemes. However, the extent to which the 
sample size limits generalisability to the wider patient 
population is unknown.
An additional limitation of the study centres on the 
reliability of self-reported compliance. The patient cohort 
who had previously experienced generic substitution 
reported that this experience had not impacted on their 
compliance. However, the reliability of self-reported 
compliance is weak due to a number of contributory fac-
tors which leads to the potential to overestimate adher-
ence. These factors include recall bias, social desirability 
bias and errors in self-observation [31]. The authors also 
acknowledge the potential for researcher bias in the con-
duct of the patient interview due to the large numbers of 
individual interviewers in the study. Finally, while pilot 
testing of the survey was undertaken, the potential for 
the wording of questions to give rise to bias is associated 
with uncertainty.
However, a useful insight into the views of stakehold-
ers has been obtained in the period immediately preced-
ing the introduction of legislation permitting generic 
substitution.
Conclusion
The findings from this study identify the high rate of 
acceptance of patients, prescribers and pharmacists in 
the Irish setting to generic medicines and participation 
in generic substitution. The existing concerns of the main 
stakeholders centrally involved in the process of generic 
substitution provide a valuable insight into the potential 
difficulties that may arise in its implementation, and the 
need for on-going reassurance and proactive dissemi-
nation of the impact of the generic substitution policy. 
There is a clear need to ensure that healthcare profes-
sionals are appropriately supported to ensure the addi-
tional time commitment involved in reassuring patients 
is minimised. The need for ex-post assessment of the leg-
islation’s impact is apparent, and should be provided for. 
The existing positive attitude to generic medicines and 
generic substitution among the key stakeholders, com-
bined with appropriate support and collaboration, should 
result in the desired increase in rates of prescribing, dis-
pensing and use of generic medicines, with an associated 
saving in the annual expenditure on medicines in the 
Irish setting.
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